Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 1997

View Archived Issues

Squalamine enters phase I for the treatment of cancer

Flt3 ligand stimulates production of fully functional dendritic cells

Penederm and Mylan to copromote Mentax

Vyrex's respiratory antioxidant shows potential as asthma therapy

Idec's immunotherapy shows promise in phase I/II for non-Hodgkin's lymphoma

Prevention of neurodegeneration in Parkinson's disease reported

Peptidomimetic inhibitors of protein farnesyltransferase from Merck & Co.

HGS discloses new cysteine protease inhibitor

In vitro and in vivo immunosuppressive effects of FTY-720

Pharmacological characterization of LY-344864, a selective 5-HT1F receptor agonist

New antiviral agent for flu disclosed in patent literature

Novel nicotinic ligand discovered by British university researchers

Isolation, structural elucidation and preliminary biological evaluation of new XOD inhibitor

Gensia pursues formation of Metabasis as separate company and announces Sankyo investment

Antibody-based therapeutics alliance formed by CAT and Icos

Schering-Plough obtains rights to Claritin metabolite from Sepracor

New antitumor agent in development in China

VasoCare therapy successfully completes E.U. regulatory approval audit

Cel-Sci and NCI to test L.E.A.P.S. in NCI animal models of cancer

ICI-182780 associated with longer remission duration than megestrol in resistant breast cancer

Life Medical Sciences terminates Piliel trials early; refocuses R&D efforts

CY-1503 reduces reperfusion injury in a dog lung allograft model

Boehringer Ingelheim and Thomae to operate as one legal entity

FDA clears Trovan, Pfizer's broad-spectrum quinolone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...